Related Experiment Video
Updated: Nov 18, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Declining US Hepatocellular Carcinoma Rates, 2014-2017.
Meredith S Shiels1, Thomas R O'Brien1
1Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
Hepatocellular carcinoma (HCC) rates in the US showed a potential decline in 2016. This study examines HCC rates through 2017 to confirm if this trend is real.
Area of Science:
- Hepatology
- Cancer Epidemiology
- Public Health
Background:
- Liver cancer, particularly hepatocellular carcinoma (HCC), is a major cause of cancer mortality in the US.
- Historically, HCC incidence rates in the US have risen significantly over several decades.
- Recent data suggested a possible flattening or decrease in HCC rates.
Purpose of the Study:
- To determine if the previously observed 4% decrease in US HCC rates in 2016 represented a true downward trend.
- To analyze the trajectory of HCC rates through 2017.
Main Methods:
- Analysis of national cancer incidence data.
- Examination of trends in hepatocellular carcinoma (HCC) rates.
Main Results:
- The study provides updated data on HCC rates through 2017.
- Confirms or refutes the downward trend observed in 2016.
Conclusions:
- The findings will clarify the recent trends in HCC incidence.
- Implications for public health strategies and cancer prevention efforts.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
10:35Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
Published on: September 25, 2013
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment